お知らせ • May 08
AnGes, Inc. to Report Q1, 2026 Results on May 08, 2026 AnGes, Inc. announced that they will report Q1, 2026 results on May 08, 2026 お知らせ • Mar 26
Vasomune Therapeutics, Inc. and Anges, Inc. Initiate Clinical Trial for Pegevongitide (Av-001) to Prevent Brain Injury in Hemodialysis Patients Vasomune Therapeutics, Inc. and AnGes, Inc. have treated the first patient in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc., and AnGes, Inc., will work to stabilize the cerebral vasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. Pegevongitide (AV-001) offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels and prevent vascular leakage. With the initiation of this study, Vasomune now moves into a new and exciting arena of working to improve cerebrovascular health in patients. Positive findings from this study will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population. お知らせ • Feb 10
AnGes, Inc., Annual General Meeting, Mar 27, 2026 AnGes, Inc., Annual General Meeting, Mar 27, 2026. お知らせ • Dec 03
AnGes, Inc. to Report Fiscal Year 2025 Results on Feb 10, 2026 AnGes, Inc. announced that they will report fiscal year 2025 results on Feb 10, 2026 お知らせ • Sep 04
Health Canada Gives Green Light to New Study Investigating Novel Made-In-Canada Drug Candidate to Prevent Brain Injury in Hemodialysis Patients A groundbreaking clinical study has been approved by Health Canada to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing acute ischemic brain injury in patients undergoing routine hemodialysis. Pegevongitide (AV-001), a made-in-Canada drug candidate codeveloped by Vasomune Therapeutics, Inc. and AnGes, Inc., will work to stabilize the cerebrovasculature, which undergoes significant circulatory stress during the hemodialysis procedure. Cerebrovascular destabilization is linked to vascular cognitive impairment in up to 70% of patients initiating routine hemodialysis. The clinical study is led by Dr. Christopher McIntyre, Professor of Medicine, Medical Biophysics, and Paediatrics at Western University and holder of the Robert Lindsay Chair of Dialysis Research and Innovation. Dr. McIntyre also serves as Director of the Lilibeth Caberto Kidney Clinical Research Unit at London Health Sciences Centre, where he practices as a Clinical Nephrologist. A recognized leader in kidney research, Dr. McIntyre leads a multidisciplinary team investigating the pathophysiological impact of chronic kidney disease on cardiovascular, neurological, hepatic, and gastrointestinal systems. His research integrates multimodal imaging with clinical and translational studies to develop and evaluate novel therapeutic strategies. His recent work increasingly focuses on mitigating the adverse consequences of dialysis therapy itself, and he has recently published about dialysis and cognitive impairment in Nature Reviews Nephrology. Patients, particularly those over 55, face a high burden of moderate-to-severe cognitive impairment, affecting up to 70% of this age group. Hemodialysis patients are uniquely vulnerable to recurrent ischemic brain injury caused by circulatory stress during treatment. "Pegevongitide ("AV-001") offers a promising new approach by targeting the Tie2/Angiopoietin-1 signaling pathway to stabilize blood vessels, prevent vascular leakage and reduce vascular inflammation. With this approval from Health Canada and the initiation of this study, Vasomune now moves into a new and exciting opportunity to improve cerebrovascular health in patients," according to Dr. Harold Kim, Vice-President of Research at Vasomune Therapeutics Inc. Published data using Pegevongitide(AV-001) demonstrated that this mechanism can improve neurological health, reduce cognitive impairment, and reduce cerebrovascular leak. The study will assess whether Pegevong it can reduce hemodialysis-induced cytotoxic brain edema and preserve white matter integrity. Advanced neuroimaging techniques, cognitive assessments, and blood biomarkers will be used to evaluate outcomes. Supported by a prestigious Heart and Stroke Foundation grant, this research has the potential to redefine how brain health is protected in hemodialysis patients. Positive findings will inform a larger confirmatory trial and could lead to improved quality-of-life and functionality for this high-risk population. お知らせ • Sep 01
AnGes, Inc. to Report Q3, 2025 Results on Nov 07, 2025 AnGes, Inc. announced that they will report Q3, 2025 results on Nov 07, 2025 お知らせ • May 31
AnGes, Inc. to Report Q2, 2025 Results on Aug 08, 2025 AnGes, Inc. announced that they will report Q2, 2025 results on Aug 08, 2025 お知らせ • Mar 01
AnGes, Inc. to Report Q1, 2025 Results on May 09, 2025 AnGes, Inc. announced that they will report Q1, 2025 results on May 09, 2025 お知らせ • Feb 14
AnGes, Inc., Annual General Meeting, Mar 28, 2025 AnGes, Inc., Annual General Meeting, Mar 28, 2025. お知らせ • Dec 03
AnGes, Inc. to Report Fiscal Year 2024 Results on Feb 07, 2025 AnGes, Inc. announced that they will report fiscal year 2024 results on Feb 07, 2025 お知らせ • Aug 27
AnGes, Inc. to Report Q3, 2024 Results on Nov 08, 2024 AnGes, Inc. announced that they will report Q3, 2024 results on Nov 08, 2024 お知らせ • Jun 02
AnGes, Inc. to Report Q2, 2024 Results on Aug 09, 2024 AnGes, Inc. announced that they will report Q2, 2024 results on Aug 09, 2024 お知らせ • Mar 23
AnGes, Inc. to Report Q1, 2024 Results on May 10, 2024 AnGes, Inc. announced that they will report Q1, 2024 results on May 10, 2024 お知らせ • Mar 20
AnGes, Inc. announced that it expects to receive ¥1.348415953 billion in funding from Cantor Fitzgerald Europe AnGes, Inc. announced a private placement of 1st unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥1,300,000,000, 2nd unsecured convertible bond type bond with stock acquisition rights for gross proceeds of ¥32,500,000, and 300,301 stock acquisition rights at a price of ¥53 per stock acquisition right for gross proceeds of ¥15,915,953, for aggregate gross proceeds of ¥1,348,415,953 on March 19, 2024. The transaction for 1st bonds is expected to close on April 5, 2024, 2nd bonds on October 7, 2024, and stock acquisition rights on April 5, 2024. The transaction included participation from new investor Cantor Fitzgerald Europe. お知らせ • Feb 11
AnGes, Inc., Annual General Meeting, Mar 28, 2024 AnGes, Inc., Annual General Meeting, Mar 28, 2024. お知らせ • Jan 19
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy (Lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan Eiger BioPharmaceuticals, Inc. announced that it and its partner AnGes, Inc. received marketing approval from the Ministry of Health, Labour and Welfare for Zokinvy (lonafarnib), a treatment for Hutchinson-Gilford progeria syndrome (HGPS) and processing deficient progeroid laminopathy (PDPL). Collectively known as progeria, HGPS and PL are devastating ultra-rare and fatal pediatric diseases that cause dramatically accelerated aging and premature death. The main cause of death is heart attack or stroke due to severe hardening of the arteries. The approval was based on the positive results of two pivotal clinical trials demonstrating that Zokinvy, an oral disease-modifying agent which targets the cause of progeria, lowered the risk of death in children by 72% and extended life by an average of 4.3 years (p<0.0001) in children and young adults with HGPS. お知らせ • Dec 05
AnGes, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024 AnGes, Inc. announced that they will report fiscal year 2023 results on Feb 09, 2024 お知らせ • Nov 15
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study Vasomune Therapeutics, Inc. announced that their lead drug candidate AV-001 has received a positive recommendation from the Independent Data and Safety Monitoring Board (IDSMB) of the AV001-004 Phase 2a Study. About AV-001: Originally discovered and designed at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, AV-001 is being developed by Vasomune Therapeutics, Inc. under a co-development agreement with AnGes, Inc. AV-001 is a novel investigational medicine that targets the Tie2 receptor, a transmembrane protein most highly expressed on the surface of endothelial cells in the vasculature. AV-001 activates the nonredundant Tie2-Angiopoietin signaling axis, and through stimulation of multiple downstream pathways normalizes the vasculature by enhancing endothelial cell stability, restoring normal barrier defense, and blocking vascular leak. Vascular dysfunction contributes to the underlying disease pathophysiology in patients with COVID-19, influenza, bacterial sepsis, acute kidney injury, glaucoma, hemorrhagic shock, sepsis, stroke, and complications associated with diabetes. Importantly, in multiple pre-clinical studies, AV-001 tightened endothelial cell-cell junctions and promoted endothelial cell survival, which reduced pulmonary edema, and improved lung function compared to untreated controls translating into significantly improved survival. お知らせ • Jul 13
AnGes, Inc. announced that it has received ¥8.481467 million in funding from BofA Securities Japan Co., Ltd. On July 12, 2023, AnGes, Inc. closed the transaction. お知らせ • Jun 27
AnGes, Inc. announced that it expects to receive ¥8.481467 million in funding AnGes, Inc. announced a private placement to issue 446,393 43rd stock acquisition right at an issue price of ¥19 per right for the gross proceeds of ¥8,481,467 on June 26, 2023. The transaction will include participation from new investor BofA Securities Co., Ltd. The transaction has been approved by the shareholders of the company and is expected to close on July 12, 2023. お知らせ • May 28
AnGes, Inc. to Report Q2, 2023 Results on Aug 09, 2023 AnGes, Inc. announced that they will report Q2, 2023 results on Aug 09, 2023 お知らせ • Dec 28
AnGes, Inc. to Report Fiscal Year 2022 Results on Feb 10, 2023 AnGes, Inc. announced that they will report fiscal year 2022 results on Feb 10, 2023